St. Joseph Heritage Healthcare

Santa Rosa, California 95405

1 studies enrolling now · 41 studies all time

What they study most

Acute Myelogenous Leukemia, Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Advanced Breast Cancer, Advanced Multiple Myeloma, Advanced Renal Cell Carcinoma, Advanced Solid Tumors, Alzheimer's Disease, Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, Bladder Cancer, Breast Cancer, Breast Cancer Metastatic, Breast Neoplasm

Studies at this site

• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements — Recruiting now
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• Avelumab Program Rollover Study — Running, not enrolling
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer — Running, not enrolling
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• Combination Study of SV-BR-1-GM With Retifanlimab — Completed
• Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer — Running, not enrolling
• Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) — Completed
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) — Stopped early
• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed
• A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) — Completed
• A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor — Completed
• A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma — Completed
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — Stopped early
• Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers — Completed
• Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) — Completed
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers — Completed
• A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) — Stopped early
• Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients — Completed
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. — Completed
• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer — Completed
• Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine — Completed
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) — Completed
• G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer — Completed
• Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy — Completed
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma — Completed
• Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients — Stopped early
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma — Completed
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors — Completed
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
• A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer — Stopped early
• Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting — Stopped early
• Registry Study for Talimogene Laherparepvec — Completed
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer — Completed
• Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax — Completed
• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC — NO_LONGER_AVAILABLE
• A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma — Completed
• A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma — Stopped early
• Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer — Stopped early
• A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation — Completed